Maxim Reaffirms Athersys (ATHX) at 'Buy'; FDA's MultiStem Message Consistent with Global Regulators

Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem® Treatment for Ischemic Stroke

CLEVELAND, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today that it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design and planned analysis of a Phase 3 clinical trial of Athersys novel MultiStem® cell therapy product for the treatment of ischemic stroke.  The SPA provides agreement from the FDA that the protocol design, clinical endpoints, planned conduct and statistical analyses encompassed in Athersys planned Phase 3 study are acceptable to support a regulatory submission for approval of the MultiStem product for treating ischemic... More